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Background: We determined the differently expressed protein profiles and their functions in bladder cancer tissues
with the aim of identifying possible target proteins and underlying molecular mechanisms for taking part in their
progression.
Methods: We examined the expression of proteins by proteomic analysis and western blot in normal urothelium,
non-muscle-invasive bladder cancers (NMIBCs), and muscle-invasive bladder cancers (MIBCs). The function of cofilin
was analyzed using T24 human bladder cancer cells.
Results: The expression levels of 12 proteins were altered between bladder cancers and normal bladder tissues. Of
these proteins, 14-3-3σ was upregulated in both NMIBCs and MIBCs compared with controls. On the other hand,
myosin regulatory light chain 2, galectin-1, lipid-binding AI, annexin V, transthyretin, CARD-inhibitor of
NF-κB-activating ligand, and actin prepeptide were downregulated in cancer samples. Cofilin, an
actin-depolymerizing factor, was prominent in both NMIBCs and MIBCs compared with normal bladder tissues.
Furthermore, we confirmed that cofilin phosphorylation was more prominent in MIBCs than in NMIBCs using
immunoblotting and immunohistochemcal analyses. Epidermal growth factor (EGF) increased the phosphorylation
of cofilin and elevated the migration in T24 cells. Knockdown of cofilin expression with small interfering RNA
attenuated the T24 cell migration in response to EGF.
Conclusions: These results demonstrate that the increased expression and phosphorylation of cofilin might play a
role in the occurrence and invasiveness of bladder cancer. We suspected that changes in cofilin expression may
participate in the progression of the bladder cancer.
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Bladder cancer is the ninth most often diagnosed and
the seventh most prevalent cancer worldwide, and shows
an increasing tendency in Asia [1]. It commonly presents
as an urothelial cell carcinoma with non-muscle-invasive
bladder cancer (NMIBC), but is clinically well controlled
and can be treated relatively easily by transurethral re-
section of bladder tumor. However, bladder cancer has a
high recurrence rate at 60–70%, and 11% of the recur-
rent cases progress to a muscle-invasive bladder cancer
(MIBC) [2,3]. It is very difficult to predict recurrence or* Correspondence: hskim@kku.ac.kr
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reproduction in any medium, provided the orprogression, or to understand bladder carcinogenesis
according to established clinical classification system.
Moreover, there are no available markers that can guide
clinicians in diagnosis, recurrence, or in decreasing the
number of unnecessary cystoscopy among patients with
bladder cancer. Therefore, new pathological and bio-
logical markers for the recurrence and progression of
bladder cancers are needed.
There are several known markers used clinically for
bladder cancer: nuclear matrix protein 22, telomerase, epi-
dermal growth factor (EGF) receptor and others [4-8].
However, these have limitations in their specificity and/or
sensitivity, as is shown by cystoscopy of bladder cancers
[4]. Celis’ group has performed proteomic and genomic
analyses to identify markers in bladder cancers [9-12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing 1, ADAM28, and annexin 1, have been identified as
markers for bladder cancer [13-16]. Moreover, real-time
polymerase chain reaction has been used to detect RNA
related with muscle invasive bladder cancer [17]. Prote-
omic analysis has also been performed using urinary and
plasma proteins from patients with bladder cancers
[18,19]. The mechanisms for bladder cancer development
and progression have not yet been fully resolved and as
such the need for more reliable and accurate biomarkers
for disease recurrence and progression remains. Protein
modifications such as phosphorylation, glycosylation or
oxidation play vital roles in the initiation and progression
of many molecular pathways. Hence, an understanding of
protein modification is crucial for identifying the key func-
tional modulators of carcinogenesis, progression and
metastasis [20]. Although previous studies have investi-
gated human bladder cancer tissues using proteomic tools
[13-16], these mainly involved protein identification and
immunohistochemistry. Therefore, further studies are
required to characterize the mechanisms of progressionTable 1 Clinical, histological and epidemiological characterist
Sex Age Clinical diagnosis Cytology
Normal urothelium, Bladder
M 32 Traumatic bladder rupture Class I
F 35 Traumatic bladder rupture Class I
M 30 Traumatic bladder rupture Class I
F 44 Traumatic bladder rupture Class I
F 38 Traumatic bladder rupture Class I
F 41 Traumatic bladder rupture Class I
Non-muscle-invasive urothelial cell cancer, Bladder
M 67 Bladder tumor Class I
M 71 Bladder tumor Class II
M 69 Bladder tumor Class II
F 66 Bladder tumor Class II
F 62 Bladder tumor Class II
M 69 Bladder tumor Class I
M 53 Bladder tumor Class I
F 68 Bladder tumor Class I
M 69 Bladder tumor Class II
Muscle-invasive urothelial cell cancer, Bladder
M 68 Bladder tumor Class III
F 72 Bladder tumor Class IV
M 63 Bladder tumor Class IV
M 67 Bladder tumor Class IV
F 71 Bladder tumor Class III
M 69 Bladder tumor Class IV
M 63 Bladder tumor Class IV
M 68 Bladder tumor Class V
M 53 Bladder tumor Class IVand invasion and to explore for potential targets for occur-
ring mechanisms of MIBC and NMIBC.
The aims of the present study were to identify proteins
that are involved in bladder cancer progression by com-
paring protein expression patterns between normal
urothelium tissues, NMIBCs, and MIBCs samples using
proteomic technique and to determine the underlying
molecular mechanism associated with the observed pro-
tein changes. We found an actin-depolymerizing factor
(ADF), cofilin, to be elevated in NMIBC and MIBC tis-
sues and further confirmed its function in cell motility
using T24 human bladder cancer cells.
Methods
Materials
A total of 24 bladder samples that used in this study
were obtained from patients with bladder cancers and
bladder rupture (Table 1; n = 6, normal urothelium; 9,
NMIBCs; 9, MIBCs). Tumors were graded according to
WHO criteria and staged according to the TNM classifi-
cation. All of the materials used for two-dimensionalics of the patients whose bladder proteins were analyzed







Urothelial cell carcinoma Grade 1 TaN0M0
Urothelial cell carcinoma Grade 2 T1N0M0
Urothelial cell carcinoma Grade 1 TaN0M0
Urothelial cell carcinoma Grade 1 TaN0M0
Urothelial cell carcinoma Grade 1 T1N0M0
Urothelial cell carcinoma Grade 2 T1N0M0
Urothelial cell carcinoma Grade 1 T1N0M0
Urothelial cell carcinoma Grade 1 TaN0M0
Urothelial cell carcinoma Grade 1 TaN0M0
Urothelial cell carcinoma Grade 3 T4aN1M0
Urothelial cell carcinoma Grade 3 T4aNxM0
Urothelial cell carcinoma Grade 3 T4bN1Mx
Urothelial cell carcinoma Grade 3 T4bN2M0
Urothelial cell carcinoma Grade 3 T4bN2Mx
Urothelial cell carcinoma Grade 2 T4bN2M0
Urothelial cell carcinoma Grade 3 T4aNxM0
Urothelial cell carcinoma Grade 3 T4aN1M0
Urothelial cell carcinoma Grade 3 T4aNxM0
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were purchased from BioRad (Hercules, CA, USA) or
Applied Biosystems (Foster City, CA, USA). Recombin-
ant human EGF was purchased from R&D Systems
(Minneapolis, MN, USA). McCoy’s 5A medium was
obtained from Welgene (Daegu, Korea). Polyclonal anti-
phosphorylated ser-3 cofilin and anti-cofilin antibodies
were obtained from Cell Signaling (Beverly, MA, USA).
Polyclonal anti-GAPDH antibody and chemical reagents
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Preparation of bladder tissue samples
All experiments were performed in accordance with the
institutional guidelines of Konkuk University and were
approved by the Institutional Review Board of Konkuk
University Chungju Hospital, Chungju-city, Korea
(KUCH 07-009). All patients had given their informed
consent to participate in the study. Urothelial samples
(0.1−1 mg) from bladder rupture were obtained from
the patients with intraperitoneal bladder rupture. The
abdomen was opened through a vertical lower mid-line
incision and then the ruptured margin of the bladder
was incised using Metzenbaum scissors. NMIBC and
MIBC tissues were removed by bladder biopsy or trans-
urethral resection. After removal of the tissues, these
were rinsed in physiological salt solution (in mM; NaCl
136.9, KCl 5.4, CaCl2 1.5, MgCl2 1.0, NaHCO3 23.8,
EDTA 0.01). The samples were then snap-frozen in
liquid N2 for proteomic and western blot analyses. The
samples for immunohistochemical assay were immersed
in 4% paraformaldehyde for 8 hr and embedded in paraf-
fin wax.
2-DE and MALDI-TOF/TOF MS
Bladder tissue samples from bladder rupture and cancer
patients were homogenized in 2-DE buffer containing 8
M urea, 2 M thiourea, 100 mM DTT, 4% CHAPS and
1 × complete protease inhibitor cocktail (Roche Applied
Science, Penzberg, Germany). The homogenates were
incubated for 40 min and then centrifuged at 12 000 × g
for 10 min at 10°C. The supernatants were diluted with
rehydration buffer containing 7 M urea, 2 M thiourea,
100 mM DTT, 2% CHAPS, 0.5% ampolyte and 0.01%
bromophenol blue, and then used for 2-DE as described
in our previous report [21-23]. Images of silver-stained
gel were visualized using a densitometer (VersoDoc Ima-
ging System 1000; Bio-Rad). The gels obtained from six
independent experiments were normalized as a percentage
of the total spot volume in all of the spots present on the
gels and analyzed statistically using PDQuest software
(Version 7.1.1, Bio-Rad).
In-gel digestion and protein identification were per-
formed as reported [21-23]. Briefly, the protein spots
were digested with trypsin and desalted with ZipTip C18(Millipore, Bedford, MA, USA). The peptide samples
were mixed with CHCA matrix solution and then ana-
lyzed by MALDI-TOF/TOF (AB4700, Applied Biosys-
tems) in the reflector mode. The search parameters were
used trypsin, 2 missed cleavage, cut-off individual ion
scores > 20, extensive homology p < 0.05, variable modi-
fication of carbamidomethyl, oxidation, propionamide
and pyro-glu (N-term), a peptide charge of 1+, and
monoisotopic. The mass accuracy was within 100 ppm
for the mass measurement and within 0.2 Da for CID
experiments. Spectra were processed and analyzed with
Global Protein Server Explorer 3.0 software (Applied
Biosystems). The internal Mascot program (Matrix
Science Ltd., London, UK) was used for matching MS
and MS/MS data against database information. The
resulting data were surveyed against human databases
downloaded from NCBI and the Swiss Prot/TrEMBL
homepages.
Immunoblotting
For immunoblotting, extracted protein samples were
diluted 1:1 (v/v) with SDS sample buffer (40 mM Tris–
HCl pH 6.8, 8 mM EGTA, 4% 2-mercaptoethanol, 40%
glycerol, 0.01% bromophenol blue, and 4% SDS) and then
denatured by boiling for 5 min. The samples (20–30 μg/
lane) were separated by 14% SDS-PAGE and transferred
electrophoretically onto polyvinylidene fluoride mem-
branes (Millipore, Bedford, MA, USA). The membrane
was blocked for 2 hr with phosphate-buffered saline con-
taining 0.05% Tween 20 and 5% fat-free dried milk. The
membrane was incubated overnight with antibodies diluted
1:1,000 and then reacted with horseradish peroxidase-
conjugated antibodies (Amersham Pharmacia Biotech Inc.,
Piscataway, NJ, USA) for 1 hr. The blots were visualized
with enhanced chemiluminescence reagents (Amersham
Pharmacia). Statistical analysis was performed using Quan-
titation software (Bio-Rad).
Immunohistochemistry
Total 24 bladder tissues from each patients were used
for the immunohistochemical analysis. Each formalin-
fixed and paraffin-embedded tissue was cut into 4-mm
thick sections, deparaffinized, rehydrated and blocked
with methanol containing 3% hydrogen peroxide. Cofilin
antibodies diluted 1:100 was then applied and incubated
for 60 min in a room temperature. After washing, the
sections were incubated with horseradish peroxidase-
conjugated dextran polymer reagent kits (ChemMate
Envision Kit K5007; DakoCytomation, Glostrup, Denmark)
for 30 min. Peroxidase activity was visualized with 3,
3’-diaminobenzidine tetrachloride according to the manu-
facturer’s instructions. The sections were counterstained
with hematoxylin at room temperature. Negative controls
were carried out by omitting the primary antibodies. The
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semiquantatively scored in three groups as follows: diffuse
strong staining (> 50%), weak or focal staining (< 50%), and
absence of any staining.
Human bladder carcinoma cell line and transfection
Human bladder cancer T24 cells that were purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA) were cultured in McCoy’s 5A medium containing
10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin,
and 200 mM glutamine. The cultured cells (8 × 104) were
replaced with FBS-free McCoy’s 5A medium, and then
transfected with the siRNA or nonsilencing control RNA
to 1,000 pM using a transfection reagent (Welfect-QTM
Gold, Welgene, Daegu, Korea). The relative protein expres-
sion levels of cofilin were examined using immunoblot-
ting analysis with anti-cofilin antibody. Cofilin siRNA
was designed to target the human cofilin sequence
5'-CCCAAACUGCUU UUGAUCU-3' (Accession number:
NM_005507; Bioneer, Daejeon, Korea). Control nonsilen-
cing RNA was purchased from Bioneer.
Migration assay
Migration assays were performed in 48-well microche-
motaxis Boyden chambers (Neuro Probe, Cabin John,
MD, USA). Polycarbonate membranes (8-μm pore size,
Neuro Probe) were coated with a 0.1 mg/mL of type I
collagen (BD Bioscience, San Diego, CA, USA) and then
dried for 60 min. Cells were harvested using trypsin-
EDTA (Life Technologies, Paisley, UK) and resuspended
in McCoy’s 5A medium containing 0.1% BSA with or with-
out EGF. The bottom chamber was loaded with 3 × 104
cells and the membrane was laid over the cells. The micro-
chamber was then inverted and incubated at 37°C for 80
min. The membranes were fixed and stained using Diff-
Quik (Baxter Healthcare, Miami, FL, USA). The number of
cells migrated through the membrane was determined byFigure 1 2-DE gel images showing protein expression in bladder tissu
samples were loaded onto nonlinear IPG strips (pH 3-10, 17 cm) in an IEF c
visualized by silver staining. The numbers are the spot numbers of detecte
bladder cancer tissues compared with controls. Representative images fromcounting four randomly chosen regions of each well under
a microscope (× 400).
Statistical analysis
Data are presented as the mean ± SD. The statistical
evaluation of data was performed using Student’s t-tests
for comparisons between pairs of groups and ANOVA
for multiple comparisons; p < 0.05 was considered to be
a statistically significant difference.
Results
Isolation and identification of differentially expressed
proteins between normal and bladder cancer tissues
First, we analyzed the differences in protein expression
levels between normal and bladder cancer tissues. The
mean matching rates for gels were about 67–72% for the
same cancer developmental stage and 60–67% between
gels for different developmental stages. Figure 1 shows
the expression pattern of proteins in normal bladder,
NMIBC and MIBC tissues. The expression level of 12
protein spots was altered by at least 1.5-fold in bladder
tissues from cancer patients compared with those
obtained from controls (Figure 2). The differentially ex-
pressed proteins were identified by MALDI-TOF/TOF
mass spectrometry (Table 2). Of these proteins, 14-3-3σ
(spot 2), macrophage-capping protein (spot 10), and
cofilin (spot 12) were upregulated in both NMIBC and
MIBC samples compared with normal human bladder
tissues. On the other hand, myosin regulatory light chain
2 (spot 1), galectin-1 (spot 3), lipid-binding AI (spot 4),
annexin V (spot 5), transthyretin (spot 6), CARD-
inhibitor of NF-κB-activating ligand (spot 8), actin pre-
peptide (spot 9), and macrophage-capping protein (spot
11) were downregulated in bladder tissues from NMIBC
and MIBC samples compared with controls (Figure 2).
Ferritin light subunit (spot 7) was only upregulated in
the cancer tissues from patients with MBIC comparedes from normal human, NMIBC and MIBC samples. The protein
ell and then separated by 12% SDS-PAGE. The protein spots were
d proteins and arrows indicate the differentially expressed proteins in
six independent experiments.
Figure 2 Expression profiles and quantitative analyses of up or downregulated proteins in NMIBC, and MIBC tissues compared with
controls. Arrows on the cropped 2-DE-gels represent proteins spots showing statistically significant changes between cancer groups and
controls. Data were obtained from 2-DE gels of six independent experiments using PDQuest software;* p < 0.05 (n = 6). White bars (a) indicate
normal human bladder tissues; striped bar (b) show bladder tissue from patients with NMIBC; black bars (c) indicate MIBC samples.
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no difference in the expression level of ferritin light
subunit between normal bladder and NMIBC tissues.
Table 2 shows the characteristics of identified protein
spots including representative peptide sequences, se-
quence coverage, theoretical and experimental pI and
Mr values, accession numbers from both the Swiss-Prot
and NCBI databases, and known functions of the identi-
fied proteins.Changes in cofilin level in cancer tissues from patients
with cancer
As shown in Figure 3A, the expressed level of cofilin
was increased markedly in both NMIBC and MIBC tis-
sues compared with normal bladder tissues. To confirm
the results of 2-DE and silver staining analysis, we exam-
ined the expression level of cofilin in bladder tissues
from controls and patients with bladder cancers using
immunoblotting and immunohistochemical analyses.
Immunoblotting showed that cofilin expression was ele-
vated in both NMIBC and MIBC samples compared
with the normal bladder tissues (Figure 3B). There were
statistical significant differences in the expression andphosphorylation of cofilin and ratio of phosphorylated
cofilin/total cofilin in bladder cancer tissue compared
with normal human bladder tissue (Figure 3C-E). The
function of cofilin is tightly regulated by its phosphoryl-
ation and dephosphorylation levels [24,25], and impli-
cated in the cancer cell motility and metastasis [26-28].
Therefore, we focused our analysis on the phosphorylation
level of cofilin in tissues from normal human bladder and
patients with bladder cancers. The phosphorylation of
cofilin was elevated in both NMIBC and MIBC samples
compared with the normal bladder tissues, and was more
prominent in MIBCs than in NMIBCs (Figures 3, 4).
By immunohistochemistry, antibodies against cofilin and
phosphorylated cofilin revealed a negative immunoreactiv-
ity in the normal bladder tissues. Cofilin stained diffusely
and strongly in all MIBCs and NMIBCs, whereas phos-
phorylated cofilin stained more in all MIBCs compared
with NMIBCs (Figure 4).
Role of cofilin in the motility of T24 human bladder
cancer cells
Recently it was reported that cofilin is implicated in cell
migration in various cells such as smooth muscle cells
and metastatic cancer cells [26,27] and EGF induces this
Table 2 Identification of differentially expressed proteins in bladder tissue from normal human, non-muscle invasive
and muscle-invasive bladder cancer patients












1 −31.16 −64.91 Myosin regulatory
light chain 2
GNFNYVEFTR 32/5 4.80/19.7 P24844/SP Regulation of cell
contractile activity(4.75/21.1)
2 2.75 1.78 14-3-3 protein σ EMPPTNPIR 20/3 4.72/27.8 631131/NC Epithelial cell
growth(4.68/30.0) P31947/SP





4 −2.92 −2.39 Lipid-binding AI DEPPQSPWDR 75/8 5.27/28.3 229513/NC Lipid binding
proteinTHLAPYSDELR (4.88/25.8)




6 −3.78 −3.50 Transthyretin GSPAINVAVHVFR 196/41 5.33/12.8 339685/NC Transports of
thyroxineAADDTWEPFASGK
ALGISPFHEHAEVVFTANDSGPR (5.07/17.0) P02766/SP
7 1 4.56 Ferritin light KPAEDEWGKTPDAMK 130/32 5.65/16.3 182516/NC Iron homeostasis
Subunit KLNQALLDLHALGSAR (5.06/22.3) P02792/SP
LGGPEAGLGEYLFER
8 −2.97 −4.88 CARD-inhibitor of DPYPVSYLR 37/2 5.14/48.8 15617462/NC Inhibitor of NF-κB
activationNF-κB-activating (5.18/25.3)
Ligand
9 −4.44 −12.69 Actin prepeptide AGFAGDDAPR 85/11 5.19/36.8 178067/NC Cell motility
AVFPSIVGRPR (5.19/52.8) P62736/SP
SYELPDGQVITIGNER
10 4.53 5.71 Macrophage
capping protein




11 −1.86 −2.31 Macrophage
capping protein





12 4.25 4.41 Cofilin AVLFCLSEDKK 98/21 8.26/18.4 P23528/SP Actin
polymerizationYALYDATYETK (7.48/19.8)
HELQANCYEEVKDR
1)non-in, non-muscle-invasive bladder cancer; invas, muscle-invasive bladder cancer; SC, sequencer coverage.
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migration was determined using T24 human bladder
cancer cells. Cofilin phosphorylation that was induced in
response to 50 ng/mL EGF showed a maximal response
at 30 sec (227.3 ± 30.0% of the control, Figure 5A and 5C),
then gradually dropped over 10 min and reached a quies-
cent level. As shown in Figure 5B and 5D, cofilin phos-
phorylation was dose dependently increased by EGF
treatment (1-100 ng/mL), and showed a maximal response
at 50 ng/mL (210.1 ± 27.8% of control). However, the EGFtreatment did not influence the levels of cofilin or GAPDH
expression.
We also tested the induction of migration in response
to EGF in T24 human bladder cancer cells. As shown
in Figure 6A, EGF (1-100 ng/mL) increased migration
of T24 cells in a dose-dependent manner, peaking at
100 ng/mL. To determine the role of cofilin phosphoryl-
ation in bladder cancer, we tested the effects of cofilin
knockdown on EGF-induced migration of T24 human
bladder cancer cells. The expression and phosphorylation
Figure 3 Expression and phosphorylation levels of cofilin in bladder tissues isolated from NMIBC, and MIBC tissues. (A) Enlargement of
cofilin spots (arrows) from 2-DE gel images obtained from normal bladder tissue, NMIBC and MIBC samples. (B) Western blot analysis of proteins
extracted from normal human bladder, NMIBC and MIBC samples. (CE) The statistical results obtained from panel B. Expression (C),
phosphorylation (D) and ratio (E) of phosphorylated to total cofilin. * p < 0.05. White bars (a), normal bladder tissue (control); striped bar (b),
NMIBC tissue; black bars (c), MIBC tissue.
Figure 4 Immunohistochemical analysis of cofilin and phosphorylated cofilin in bladder tissues from bladder rupture and from
patients with noninvasive and invasive cancers. Paraffin-wax-embedded sections were processed using polyclonal antibodies to cofilin and
phosphorylated cofilin. A negative control was performed by omitting the primary antibodies.
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Figure 5 EGF-induced phosphorylation of cofilin in human bladder cancer T24 cells were stimulated with EGF (50 ng/mL) for the
indicated times (A), and with a range of EGF concentrations (1–100 ng/mL) for 30 sec (B). The cell lysates were immunoblotted with anti-
phosphorylated ser-3 and anti-nonphosphorylated cofilin antibodies. (C) and (D) show statistical results obtained from the upper panels (A) and
(B), respectively. The basal levels of cofilin phosphorylation are expressed as 100%. * denotes a statistically significantly difference from the basal
levels of cofilin phosphorylation (p < 0.05).
Figure 6 Effects of cofilin knockdown on EGF-induced migration in human bladder cancer T24 cells. (A) The effect of EGF on cell
migration. Cells were treated with EGF (1–100 ng/mL) for 80 min and migration was quantified with a Boyden microchemotaxis chamber assay.
(B) Non-phosphorylated and phosphorylated cofilin expression in human bladder cancer T24 cells transfected with small interfering (si)RNA for
cofilin. (C) Effects of siRNA-cofilin transfection on EGF-induced migration. The transfected cells were treated with EGF (50 ng/mL) and then
subjected to migration assays. Migration in the quiescent state is expressed as 100%. * p < 0.05. Con, control; NS, nonsilencing siRNA; siRNA,
siRNA for cofilin; p-cofilin, phosphorylated cofilin.
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were transfected with siRNA-cofilin (Figure 6B). More-
over, siRNA-cofilin significantly inhibited cell migration
(134.6 ± 3.24% of control) in response to EGF (50 ng/mL)
(Figure 6C). The responses in cells transfected with nonsi-
lencing RNA was not significantly different from the non-
transfected controls.
Discussion
In proteomics analysis, we found that the expression of
cofilin was significantly increased in bladder cancers with-
out difference between NMIBC and MIBC samples. This
was confirmed by immunoblotting with an anti-cofilin
antibody. Cofilin is found in bladder cancer cell lines [30].
It is a ubiquitously expressed ADF in a variety of cells and
plays a crucial role in the formation of actin filaments
by regulating polymerization and depolymerization [29].
Hence, cofilin is capable of stimulating the disassembly
and severing of actin filaments at or near the pointed end,
thereby continuously supplying actin for polymerizing and
rapid turnover of actin filaments [27,29]. The actin cyto-
skeleton is an essential framework for the control of a
variety of cellular functions and is required in cell migra-
tion. Cofilin is the most abundant isoform of ADF found
in invasive tumor cells [31]. Up and downregulation of
cofilin correlate with increases and decreases, respectively,
in the motility of tumor cells [32]. Cofilin is also asso-
ciated with carcinoma progression and is a marker for
breast cancer [33,34]. Reactive oxygen species (ROS) are
involved in the development of cancer [35], and cofilin ex-
pression was changed during high ROS states in vascular
smooth muscle [22]. Cofilin is dynamically regulated by
cycles of phosphorylation such that the local concentra-
tions of kinases and phosphatases determine the overall
balance of cofilin activity [36]. Thereafter, we suspected
that changes in cofilin expression are involved in the acti-
vation of cell-cycle and consequently participate in the
progression of the bladder cancer. Presently, there are no
clinically acceptable markers for early initial diagnosis or
diagnosis of bladder cancer recurrences and guide us in
reducing the frequency of the need for cystoscopy in
patients with bladder cancer. Therefore, new biological
and prognostic markers for the prediction of tumor recur-
rence and progression are needed. Further analysis using
urine or blood samples will clarify the possibility of cofilin
as an available biomarker of MIBC or NMIBC.
The activity of cofilin is regulated by phosphorylation
of its ser-3 residue, which is induced by LIM kinase
(LIMK) 1 and 2, or related testicular protein kinase
(TESK) types 1 and 2 [26]. Several phosphatases, such as
slingshot and chronophin, control the activity of cofilin
via dephosphorylation [27,30] and are tightly associated
with the invasion of cancer cells [34]. These results
imply that cofilin phosphorylation has a role indetermining the invasion and metastasis of cancer cells.
In our results, the cofilin expression increased in both
NMIBC and MIBC compared to normal bladder tissues.
However, there were no significant differences in NMIBC
and MIBC. In addition, we found that phosphorylated cofi-
lin was greater in MIBC than in NMIBC. Moreover, the
ratio of phosphorylated to total cofilin was also higher in
MIBC than in NMIBC (Figure 3). Taken together, we sug-
gest that the increased expression and phosphorylation of
cofilin might be involved in the occurrence and invasive-
ness of bladder cancer, respectively. Thereafter, our findings
indicate that cofilin could be a therapeutic target in pre-
venting the occurrence and invasiveness of bladder cancers.
In this study, EGF elevated the phosphorylation of cofi-
lin without altering its expression level and induced the
migration of T24 bladder cancer cells. These responses
were inhibited in bladder cancer cells when cofilin expres-
sion was blocked with siRNA-cofilin, confirming that cofi-
lin participates in the motility of bladder cancer cells. EGF
induces the invasion and metastasis of cancer cells [37]
and the EGF receptor is over-expressed in a number of
human malignancies such as cancers of the lung, brain,
breast and bladder [38,39]. EGF also increases the activity
of LIMK in carcinoma cells and LIMK is upregulated in
invasive mammary carcinomas [31,33]. These results im-
ply that cofilin phosphorylation participates in the motile
response to EGF in bladder cancer cells. Therefore, it
appears that EGF is involved in bladder cancer cell inva-
sion via cofilin phosphorylation.
Two protein spots corresponding with macrophage-
capping protein were observed in the whole proteome
from both human bladder cancers and normal tissues.
Moreover, the acidic form of macrophage-capping pro-
tein (spot 10) was increased significantly, but the basic
form (spot 11) was decreased in bladder cancer tissues
compared with controls, without any change in total
expression. Modifications involving changes in molecu-
lar weight and/or pI observed on 2-DE gels are impli-
cated in the activation of proteins in a variety of cells
[23]. Previously, we reported that changes in phosphor-
ylation and pI shift of proteins were found during oxida-
tive stress in vascular smooth muscle and hypertensive
vessels [22]. These results imply that the modification,
but not total expression, of macrophage-capping protein
occurs during bladder cancer progression. Although
macrophage-capping protein expression was found to be
increased in leukemic cancer cells [40], the physiological
and pathophysiological roles of this protein have not
been fully determined. Further analysis will establish the
potential of cofilin as a biomarker for MIBC or NMIBC.
Previous reports demonstrate that annexin V and trans-
thyretin were downregulated and galectin-1 was increased
in bladder cancer [41-43]. Moreover, we identified lipid-
binding AI, ferritin light subunit, and CARD-inhibitor of
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http://www.biomedcentral.com/1471-2407/13/45NF-κB that have not been reported in bladder tissues. In
this study, bladder cancers showed upregulated expression
of 14-3-3σ (spot 2) whereas myosin regulatory light chain
2 (spot 1), galectin-1 (spot 3), lipid-binding AI (spot 4),
annexin V (spot 5), transthyretin (spot 6), CARD-inhibitor
of NF-κB-activating ligand (spot 8) and actin prepeptide
(spot 9) were downregulated. Some of these changed pro-
teins, as well as cofilin are related to cell motility. Myosin
regulatory light chain 2 and 14-3-3σ are known as pro-
teins that regulate cell motility, including migration, inva-
sion and metastasis. Moreover, 14-3-3ζ binds to cofilin
and increases its phosphorylation by inhibiting cofilin
phosphatase [44]. From these results, it can be assumed
that the 14-3-3 protein participates in the progression of
bladder cancer via cofilin phosphorylation. In contrast to
the present result, a previous report showed that 14-3-3 σ
was downregulated in MIBC tissues [9]. This discrepancy
could be explained by a difference in the isoforms ex-
pressed on 2-DE gels. Here, we also found that the expres-
sion of ferritin light subunit (spot 7) was greater, those of
CARD-inhibitor of NF-κB-activating ligand (spot 8) and
actin prepeptide (spot 9) lesser in MIBC than in NMIBC
tissues. Therefore, beside cofilin phosphorylation, ferritin
light subunit, CARD-inhibitor of NF-κB-activating ligand
and actin prepeptide could be a marker of invasive cancers
compared with NMIBC.
Conclusions
We found that the expression levels of 12 proteins were
altered in bladder cancers compared with normal blad-
der tissue. Of these changes in cofilin expression levels
were prominent in both NMIBC and MIBC. Cofilin
phosphorylation was greater in MIBC than in NMIBC.
Knockdown of cofilin attenuated the EGF-induced
migrations of T24 human bladder cancer cells. Our
results showed that the increases in the expression and
phosphorylation of cofilin might play a crucial role in
the occurrence and invasiveness of bladder cancers. It is
suggested that cofilin phosphorylation could participate
to the invasiveness of human bladder cancer.
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